CompletedPHASE1, PHASE2NCT02141451

ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

Studying Diffuse large B-cell lymphoma with chronic inflammation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Masonic Cancer Center, University of Minnesota
Principal Investigator
Veronika Bachanova, MD
University of Minnesota Medical Center, Fairview
Intervention
Rituximab(drug)
Enrollment
30 target
Eligibility
18 years · All sexes
Timeline
20142019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02141451 on ClinicalTrials.gov

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

See all trials for Diffuse large B-cell lymphoma with chronic inflammation

← Back to all trials